Details of the Drug

General Information of Drug (ID: DMZ9BMU)

Drug Name

Colistimethate

Synonyms

Colimicina; Colimyscine; Colimycin M; Colistimethale Sodium; Colistimethate sodium; Colistin Sulfomethate; Colistin methanesulfonate sodium salt; Colistin sodium methanesulfonate; Colistin sodium methanesulfonate from bacillus colistinus; Colistin sulfomethate sodium; Colistinemethanesulfonate sodique; Colistrimethate sodium; Colymycin M; Pentasodium colistinmethanesulfonate; Sodium colistimethate; Sodium colistin methanesulfonate; Sodium colistinemethanesulfonate; W 1929; Colistimethate sodium [USAN:INN]; Colistinmethanesulfonic acid, sodium salt; Coly-Mycin M; Coly-Mycin M Parenteral; Coly-mycin injectable

Indication

Disease Entry	ICD 11	Status	REF
Respiratory tract infection	CA45	Approved	[1], [2]

Therapeutic Class

Antibiotics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski):
4

Molecular Weight

1749.8

Topological Polar Surface Area

Not Available

Rotatable Bond Count

39

Hydrogen Bond Donor Count

18

Hydrogen Bond Acceptor Count

33

ADMET Property

Absorption: The drug is very poor absorption from gastrointestinal tract [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 2 - 3 hours [4]

Chemical Identifiers

Formula: C58H105N16Na5O28S5
IUPAC Name: pentasodium;[2-[17-(1-hydroxyethyl)-22-[[2-[[3-hydroxy-2-[[2-(6-methyloctanoylamino)-4-(sulfonatomethylamino)butanoyl]amino]butanoyl]amino]-4-(sulfonatomethylamino)butanoyl]amino]-5,8-bis(2-methylpropyl)-3,6,9,12,15,18,23-heptaoxo-11,14-bis[2-(sulfonatomethylamino)ethyl]-1,4,7,10,13,16,19-heptazacyclotricos-2-yl]ethylamino]methanesulfonate
Canonical SMILES: CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC(C(C)O)C(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCNCS(=O)(=O)[O-])CC(C)C)CC(C)C)CCNCS(=O)(=O)[O-])CCNCS(=O)(=O)[O-])C(C)O.[Na+].[Na+].[Na+].[Na+].[Na+]
InChI: InChI=1S/C58H110N16O28S5.5Na/c1-9-35(6)12-10-11-13-46(77)65-38(14-20-59-28-103(88,89)90)53(82)74-48(37(8)76)58(87)70-41(17-23-62-31-106(97,98)99)50(79)68-43-19-25-64-57(86)47(36(7)75)73-54(83)42(18-24-63-32-107(100,101)102)67-49(78)39(15-21-60-29-104(91,92)93)69-55(84)44(26-33(2)3)72-56(85)45(27-34(4)5)71-52(81)40(66-51(43)80)16-22-61-30-105(94,95)96;;;;;/h33-45,47-48,59-63,75-76H,9-32H2,1-8H3,(H,64,86)(H,65,77)(H,66,80)(H,67,78)(H,68,79)(H,69,84)(H,70,87)(H,71,81)(H,72,85)(H,73,83)(H,74,82)(H,88,89,90)(H,91,92,93)(H,94,95,96)(H,97,98,99)(H,100,101,102);;;;;/q;5*+1/p-5
InChIKey: IQWHCHZFYPIVRV-UHFFFAOYSA-I

Cross-matching ID

PubChem CID: 216258
CAS Number: 8068-28-8
DrugBank ID: DB01111
TTD ID: D0Q3BV

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Dihydropteroate synthetase (Bact folP)	TT4ILYC	DHPS_ECOLI	Binder	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Colistimethate (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Decreased renal excretion of Colistimethate caused by Remdesivir mediated nephrotoxicity.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[13]
Inotersen	DMJ93CT	Major	Increased risk of nephrotoxicity by the combination of Colistimethate and Inotersen.	Amyloidosis [5D00]	[14]
Iodipamide	DMXIQYS	Major	Increased risk of nephrotoxicity by the combination of Colistimethate and Iodipamide.	Cholelithiasis [DC11]	[15]
Atracurium	DM42HXN	Major	Additive neuromuscular blocking effects by the combination of Colistimethate and Atracurium.	Corneal disease [9A76-9A78]	[16]
Mivacurium	DM473VD	Major	Additive neuromuscular blocking effects by the combination of Colistimethate and Mivacurium.	Corneal disease [9A76-9A78]	[16]
Pancuronium	DMB0VY8	Major	Additive neuromuscular blocking effects by the combination of Colistimethate and Pancuronium.	Corneal disease [9A76-9A78]	[16]
Tubocurarine	DMBZIVP	Major	Additive neuromuscular blocking effects by the combination of Colistimethate and Tubocurarine.	Corneal disease [9A76-9A78]	[16]
Exjade	DMHPRWG	Major	Increased risk of nephrotoxicity by the combination of Colistimethate and Exjade.	Mineral absorption/transport disorder [5C64]	[17]
Everolimus	DM8X2EH	Major	Increased risk of nephrotoxicity by the combination of Colistimethate and Everolimus.	Renal cell carcinoma [2C90]	[18]
Temsirolimus	DMS104F	Major	Increased risk of nephrotoxicity by the combination of Colistimethate and Temsirolimus.	Renal cell carcinoma [2C90]	[18]
Pipecuronium	DM5F84A	Major	Additive neuromuscular blocking effects by the combination of Colistimethate and Pipecuronium.	Tonus and reflex abnormality [MB47]	[16]
Doxacurium	DMKE7L9	Major	Additive neuromuscular blocking effects by the combination of Colistimethate and Doxacurium.	Tonus and reflex abnormality [MB47]	[16]
Vecuronium	DMP0UK2	Major	Additive neuromuscular blocking effects by the combination of Colistimethate and Vecuronium.	Tonus and reflex abnormality [MB47]	[16]
Olsalazine	DMZW9HA	Moderate	Increased risk of nephrotoxicity by the combination of Colistimethate and Olsalazine.	Ulcerative colitis [DD71]	[19]
-----------


⏷ Show the Full List of 14 DDI Information of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 064216.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999 Sep;33(9):960-7.
6	In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs. Antimicrob Agents Chemother. 1995 Apr;39(4):948-52.
7	Sulfadiazine/hydroxypropyl-beta-cyclodextrin host-guest system: Characterization, phase-solubility and molecular modeling. Bioorg Med Chem. 2008 May 15;16(10):5788-94.
8	Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
9	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
10	Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob Agents Chemother. 1995 Aug;39(8):1756-63.
11	A confirmatory method for the simultaneous extraction, separation, identification and quantification of Tetracycline, Sulphonamide, Trimethoprim an... J Chromatogr A. 2009 Nov 13;1216(46):8110-6.
12	Structures of gramicidins A, B, and C incorporated into sodium dodecyl sulfate micelles. Biochemistry. 2001 Oct 2;40(39):11676-86.
13	Cerner Multum, Inc. "Australian Product Information.".
14	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
15	Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
16	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
17	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
18	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
19	Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]